Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Down 56.2% in September

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) saw a large decrease in short interest in September. As of September 15th, there was short interest totaling 54,200 shares, a decrease of 56.2% from the August 31st total of 123,800 shares. Currently, 10.7% of the shares of the company are short sold. Based on an average trading volume of 252,000 shares, the days-to-cover ratio is presently 0.2 days. Based on an average trading volume of 252,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 10.7% of the shares of the company are short sold.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Salarius Pharmaceuticals to a “sell” rating in a report on Friday, August 22nd.

Salarius Pharmaceuticals Price Performance

SLRX stock opened at $3.89 on Friday. Salarius Pharmaceuticals has a 1-year low of $3.64 and a 1-year high of $108.00. The company has a market capitalization of $1.98 million, a price-to-earnings ratio of -0.09 and a beta of 0.44. The business has a 50 day simple moving average of $6.16 and a two-hundred day simple moving average of $9.88.

Salarius Pharmaceuticals (NASDAQ:SLRX) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($33.00) by $32.55.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.